- Postmenopausal females.
- Patients who have had surgical treatment for histological confirmed breast cancer
that was non-metastatic at the time of the initial diagnosis.
- Patients who are disease-free after 2 or 3 years of adjuvant tamoxifen treatment.
- Patients whose tumour was estrogen receptor positive (ER+).
- Evidence of a personally signed and dated informed consent document indicating that
the subject (or a legally acceptable representative) has been informed of all
pertinent aspects of the study.
- Patients for whom Aromasin® treatment is contraindicated (see SPC).
- Presence of metastasis or a contra lateral tumour.
- Other adjuvant endocrine therapy.
- Another concomitant antineoplastic treatment.
- Participation in a clinical trial with an investigational drug during the 30 days
prior to enrolment in the study.